Astellas takes stake in gene therapy developer Taysha

Japanese drugmaker Astellas will invest $50 million into Taysha Gene Therapies, gaining access to the Dallas, Texas-based biotechnology company’s pipeline of experimental treatments in a deal announced Monday.